Cargando…

Does Etelcalcetide reverse myelofibrotic bone changes due to hyperparathyroidism? A case report

Secondary hyperparathyroidism (SHPT) in dialysis is common. A young man on chronic hemodialysis with SHPT developed pancytopenia with resistant anemia requiring transfusions. A bone marrow biopsy showed grade 3 fibrosis, depleted cellularity, osteosclerosis, and decreased myelopoiesis. He initiated...

Descripción completa

Detalles Bibliográficos
Autores principales:	Panuccio, Vincenzo Antonio, Tripepi, Rocco, Postorino, Adele, Greve, Bruna, Sabattini, Elena, Oliva, Esther Natalie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9995371/ https://www.ncbi.nlm.nih.gov/pubmed/36910010 http://dx.doi.org/10.3389/fmed.2022.1050062

Ejemplares similares

Etelcalcetide in Patients on Hemodialysis with Severe Secondary Hyperparathyroidism. Multicenter Study in “Real Life”
por: Russo, Domenico, et al.
Publicado: (2019)

Correction: Etelcalcetide in Patients on Hemodialysis with Severe Secondary Hyperparathyroidism. Multicenter Study in “Real Life”. J. Clin. Med. 2019, 8, 1066
por: Russo, Domenico, et al.
Publicado: (2020)

Paget’s Disease and Secondary Hyperparathyroidism: Is Healing Possible?
por: Panuccio, Vincenzo Antonio, et al.
Publicado: (2020)

Managing hyperparathyroidism in hemodialysis: role of etelcalcetide
por: Eidman, Keith E, et al.
Publicado: (2018)

Treatment of secondary hyperparathyroidism: the clinical utility of etelcalcetide
por: Cozzolino, Mario, et al.
Publicado: (2017)

Etelcalcetide Is Effective at All Levels of Severity of Secondary Hyperparathyroidism in Hemodialysis Patients
por: Cunningham, John, et al.
Publicado: (2019)

An integrated analysis of safety and tolerability of etelcalcetide in patients receiving hemodialysis with secondary hyperparathyroidism
por: Block, Geoffrey A., et al.
Publicado: (2019)

One-year safety and efficacy of intravenous etelcalcetide in patients on hemodialysis with secondary hyperparathyroidism
por: Bushinsky, David A, et al.
Publicado: (2019)

One-year safety and efficacy of intravenous etelcalcetide in patients on hemodialysis with secondary hyperparathyroidism
por: Bushinsky, David A, et al.
Publicado: (2019)

Effects of etelcalcetide on fibroblast growth factor 23 in patients with secondary hyperparathyroidism receiving hemodialysis
por: Wolf, Myles, et al.
Publicado: (2019)

Population Pharmacokinetics and Pharmacodynamics of the Calcimimetic Etelcalcetide in Chronic Kidney Disease and Secondary Hyperparathyroidism Receiving Hemodialysis
por: Chen, P, et al.
Publicado: (2016)

A Single- and Multiple-Dose, Multicenter Study of Etelcalcetide in Japanese Hemodialysis Patients With Secondary Hyperparathyroidism
por: Yokoyama, Keitaro, et al.
Publicado: (2017)

Influence of dialysate Ca concentrations on the therapeutic effects of etelcalcetide with concomitant drugs in patients with secondary hyperparathyroidism
por: Shigematsu, Takashi, et al.
Publicado: (2019)

Control of hyperparathyroidism with the intravenous calcimimetic etelcalcetide in dialysis patients adherent and non-adherent to oral calcimimetics
por: Arenas, Maria Dolores, et al.
Publicado: (2020)

Real-World Experience of Using Etelcalcetide for Secondary Hyperparathyroidism in Community-Based Hemodialysis Centers in Singapore
por: Khan, Behram A, et al.
Publicado: (2023)

Quantitative histological image analyses of reticulin fibers in a myelofibrotic mouse
por: Lucero, Hector A., et al.
Publicado: (2016)

Role of etelcalcetide in the management of secondary hyperparathyroidism in hemodialysis patients: a review on current data and place in therapy
por: Friedl, Claudia, et al.
Publicado: (2018)

A Prospective, Randomized Clinical Trial of Etelcalcetide in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism (the DUET Trial)
por: Itano, Yuya, et al.
Publicado: (2020)

A case of a hemodialysis patient with secondary hyperparathyroidism who was resistant to etelcalcetide treatment but not to cinacalcet hydrochloride
por: Nakamura, Hironori, et al.
Publicado: (2021)

Myelofibrotic and leukemic transformation in 2016 WHO-defined Philadelphia-negative myeloproliferative neoplasm
por: Song, Ik-Chan, et al.
Publicado: (2022)

Etelcalcetide, A Novel Calcimimetic, Prevents Vascular Calcification in A Rat Model of Renal Insufficiency with Secondary Hyperparathyroidism
por: Yu, Longchuan, et al.
Publicado: (2017)

New scenarios in secondary hyperparathyroidism: etelcalcetide. Position paper of working group on CKD-MBD of the Italian Society of Nephrology
por: Bellasi, Antonio, et al.
Publicado: (2019)

Severe hypercalcaemia early after kidney transplantation in two patients with severe secondary hyperparathyroidism previously treated with etelcalcetide
por: Dachy, Guillaume, et al.
Publicado: (2021)

Pro-inflammatory cytokines and bone fractures in CKD patients. An exploratory single centre study
por: Panuccio, Vincenzo, et al.
Publicado: (2012)

Clinical Features, Gene Alterations, and Outcomes in Prefibrotic and Overt Primary and Secondary Myelofibrotic Patients
por: Kim, Tong-Yoon, et al.
Publicado: (2022)

Novel agents and evolving strategies in myelofibrotive neoplasm: an update from 2022 ASH annual conference
por: Wang, Andrew, et al.
Publicado: (2023)

Clinical Epidemiology of Systolic and Diastolic Orthostatic Hypotension in Patients on Peritoneal Dialysis
por: Torino, Claudia, et al.
Publicado: (2021)

Treatment of secondary hyperparathyroidism in patients on hemodialysis using a novel synthetic peptide calcimimetic, etelcalcetide: a short-term clinical study
por: Mima, Akira, et al.
Publicado: (2018)

Safety and efficacy of etelcalcetide, an intravenous calcimimetic, for up to 52 weeks in hemodialysis patients with secondary hyperparathyroidism: results of a post-marketing surveillance in Japan
por: Yokoyama, Keitaro, et al.
Publicado: (2020)

Etelcalcetide and Paricalcitol in Chronic Kidney Disease: When the Target Is Inflammation
por: D’Marco, Luis, et al.
Publicado: (2022)

Determination of Etelcalcetide Biotransformation and Hemodialysis Kinetics to Guide the Timing of Its Dosing
por: Edson, Katheryne Z., et al.
Publicado: (2016)

A reversible case of rapidly progressive dementia—Hypercalcemia due to hyperparathyroidism
por: de Oliveira Martins Duarte, Josiana, et al.
Publicado: (2019)

Sleep‐Disordered Breathing and 24‐Hour Ambulatory Blood Pressure Monitoring in Renal Transplant Patients: Longitudinal Study
por: Mallamaci, Francesca, et al.
Publicado: (2020)

Theoretical overview of clinical and pharmacological aspects of the use of etelcalcetide in diabetic patients undergoing hemodialysis
por: Ye, Jianzhen, et al.
Publicado: (2018)

Etelcalcetide Inhibits the Progression of Left Atrial Volume Index Compared to Alfacalcidol in Hemodialysis Patients
por: Dörr, Katharina, et al.
Publicado: (2023)

Home Pulse Pressure Predicts Death and Cardiovascular Events in Peritoneal Dialysis Patients
por: Panuccio, Vincenzo, et al.
Publicado: (2023)

Effect of etelcalcetide on cardiac hypertrophy in hemodialysis patients: a randomized controlled trial (ETECAR-HD)
por: Dörr, Katharina, et al.
Publicado: (2019)

Lessons from effect of etelcalcetide on left ventricular hypertrophy in patients with end-stage kidney disease
por: Dörr, Katharina, et al.
Publicado: (2022)

Acute and Severe Hypercalcemia Early After Kidney Transplantation in a Patient Previously Treated With Etelcalcetide
por: Foguenne, Maxime, et al.
Publicado: (2023)

Recurrent renal hyperparathyroidism due to parathyromatosis
por: Vulpio, Carlo, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_hpv33ru9af6vfumnk4uav2ffqq